Certara Inc.
| NASDAQ: CERT |
| Healthcare / Biotechnology / USA |
| 22.54 | +0.3700 | +1.67% | Vol 997.79K | 1Y Perf -17.95% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 21.79 | ASK | 23.08 | ||
| Open | 22.52 | Previous Close | 22.17 | ||
| Pre-Market | - | After-Market | 22.54 | ||
| - - | - -% |
| Target Price | 26.25 | Analyst Rating | Strong Buy 1.40 | |
| Potential % | 16.46 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 53.08 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★ 50.51 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 21.72 | Earnings Rating | — | |
| Market Cap | 3.60B | Earnings Date | 4th Aug 2022 | |
| Alpha | -0.03 | Standard Deviation | 0.16 | |
| Beta | 1.53 |
Today's Price Range 22.3023.11 | 52W Range 16.1845.48 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 23.37% | ||
| 1 Month | 16.97% | ||
| 3 Months | 5.33% | ||
| 6 Months | -23.26% | ||
| 1 Year | -17.95% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -1.32 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -0.90 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -0.20 | |||
Return on invested Capital Q | 0.31 | |||
Return on invested Capital Y | -0.08 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 4.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -203.00 | ||||
| 2.79 | ||||
| 9.70 | ||||
| 42.60 | ||||
| -13.90 | ||||
| 0.43 | ||||
| -18.17 | ||||
| 6.56 | ||||
| 3.04B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.20 | ||||
| 3.40 | ||||
| 0.22 | ||||
| 0.29 | ||||
| 0.90 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 60.70 | ||||
| 5.00 | ||||
| 20.70 | ||||
| - | ||||
| -3.95 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 300.94M | ||||
| 1.88 | ||||
| 18.48 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2022 | 0.11 | 0.11 | 0.00 |
| Q04 2021 | 0.09 | 0.01 | -88.89 |
| Q03 2021 | 0.06 | 0.07 | 16.67 |
| Q02 2021 | 0.05 | 0.03 | -40.00 |
| Q01 2021 | 0.04 | 0.06 | 50.00 |
| Q04 2020 | -0.42 | -0.37 | 11.90 |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 4th Aug 2022 |
| Estimated EPS Next Report | 0.11 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 997.79K |
| Shares Outstanding | 159.84K |
| Shares Float | 116.25M |
| Trades Count | 11.92K |
| Dollar Volume | 22.60M |
| Avg. Volume | 542.68K |
| Avg. Weekly Volume | 571.45K |
| Avg. Monthly Volume | 538.16K |
| Avg. Quarterly Volume | 518.43K |
Certara Inc. (NASDAQ: CERT) stock closed at 22.54 per share at the end of the most recent trading day (a 1.67% change compared to the prior day closing price) with a volume of 997.79K shares and market capitalization of 3.60B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 899 people. Certara Inc. CEO is William F. Feehery.
The one-year performance of Certara Inc. stock is -17.95%, while year-to-date (YTD) performance is -20.69%. CERT stock has a five-year performance of %. Its 52-week range is between 16.175 and 45.48, which gives CERT stock a 52-week price range ratio of 21.72%
Certara Inc. currently has a PE ratio of -203.00, a price-to-book (PB) ratio of 2.79, a price-to-sale (PS) ratio of 9.70, a price to cashflow ratio of 42.60, a PEG ratio of 2.32, a ROA of -0.90%, a ROC of -0.20% and a ROE of -1.32%. The company’s profit margin is -3.95%, its EBITDA margin is 20.70%, and its revenue ttm is $300.94 Million , which makes it $1.88 revenue per share.
Of the last four earnings reports from Certara Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.11 for the next earnings report. Certara Inc.’s next earnings report date is 04th Aug 2022.
The consensus rating of Wall Street analysts for Certara Inc. is Strong Buy (1.4), with a target price of $26.25, which is +16.46% compared to the current price. The earnings rating for Certara Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Certara Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Certara Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.75, ATR14 : 1.23, CCI20 : 238.98, Chaikin Money Flow : -0.02, MACD : 0.33, Money Flow Index : 73.50, ROC : 16.55, RSI : 66.68, STOCH (14,3) : 91.00, STOCH RSI : 1.00, UO : 63.49, Williams %R : -9.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Certara Inc. in the last 12-months were:
Certara Inc.
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
CEO: William F. Feehery
Telephone: +1 609 716-7900
Address: 100 Overlook Center, Princeton 08540, NJ, US
Number of employees: 899
